Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
On November 19, the Biotechnology Innovation Organization (BIO) Clinical Trial Diversity Summit brought together a dynamic mix of researchers, industry leaders, policymakers, and community […]
BIO Clinical Trial Diversity Summit explores advancing equity in clinical research Read More »
Biotech apples designed to last longer, taste great, and make superior cider were the stars when Rep. Dan Newhouse (R-WA) toured Okanagan Specialty Fruits’
Rep. Newhouse: ‘Tremendous potential’ for biotech apples in U.S. food supply Read More »
Pictured, from left: Scott McMurray, Deputy Commissioner, Georgia Quick Start; Dave Penake, CEO, Saol Therapeutics; Margie Battle, Manager, Georgia BioScience Training Center; Megan Heaphy,
Rep. Hank Johnson and BIO tour biotech training facility in Atlanta Read More »
Means for improving global food security by ensuring smallholder farmers have access to the latest innovations in crop genetics will be explored in a
World Food Prize panel to explore global food security through crop genetics Read More »
Patient advocates from across the country gathered in Washington, D.C., on October 23-24 for the BIO Patient and Health Advocacy Summit (PHAS). This event
PHAS 2024: Patient advocates unite to share stories and address barriers to treatment Read More »
“All of us have been paying attention and seeing the ‘AI high’ for the last several years,” said Ruchita Sinha, MBA, General Partner at
BIF 2024: AI experts discuss use cases, benefits, ROI Read More »
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the
BIO Investor Forum panel breaks down when, what, and why of IPOs Read More »
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the
BIF 2024: ‘The IRA really disrupted how we think’ Read More »
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in
BIO Investor Forum opens with encouraging news on financing Read More »
There is a great degree of renewed optimism for drug development in the neurodegenerative disease space. “Some of that optimism has obviously come from
BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Read More »
